NEMUS Bioscience Announces Data Accepted for Presentation

NEMUS Bioscience (OTCQB:NMUS) announced the set of data it submitted for presentation at the upcoming Society of Neuroscience annual meeting.
As quoted in the press release:

The data being presented will show the superiority of the NEMUS proprietary analogue of CBD, NB2222, versus plant-derived CBD in ameliorating pain in a validated mouse (murine) model of chemotherapy-induced peripheral neuropathy using an opioid as an active comparator. Additional data will also be presented detailing the anti-addictive potential of NB2222 in an animal model of opioid addiction. The in vivo research was led by Professor Kenneth Sufka of the University of Mississippi based on the molecular cannabinoid discovery work performed by the team at ElSohly Laboratories, Inc. (ELI) in collaboration with the University, spearheaded by Dr. Mahmoud ElSohly, who also holds a faculty appointment at the University.
“NEMUS has previously reported that our proprietary analogue of CBD, NB2222, has exhibited a competitive bioavailability profile when compared to plant-derived CBD, penetrating the blood-brain barrier to enter the central nervous system, as well as all major organs, especially the liver, in animal studies conducted to-date,” commented Brian Murphy, MD, MBA, the NEMUS CEO and Chief Medical Officer. “The data being presented by Dr. Sufka is a pivotal start to developing the analogue of CBD to potentially address medical indications in multiple organ systems, especially the eye, brain and diseases of the liver.”

Click here to read the full press release.

Source: www.marketwired.com